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ABSTRACT
Cancer always presents a big problem that endangers human health. In recent years, the use of gene therapy in cancer 
research has significantly increased. This study aimed to construct a non-viral, wild-type, recombinant eukaryotic 
expression vector, pEGFP-N1-p53/MAR and verify its mechanism of action in cancer cells in vitro. This investigation 
provides a novel strategy for p53 gene therapy via regulation of the matrix attachment region (MAR), potentially laying a 
foundation for the establishment of an anticancer protein bioreactor. The p53 gene was cloned from human peripheral blood 
and the MAR gene was amplified from chicken liver tissue. The recombinant eukaryotic expression vector pEGFP-N1-p53/
MAR was constructed using an E. coli self-replication system. LipofectamineTM 2000 was used as the transfection agent 
to deliver the plasmid into the human hepatic carcinoma (HEP3B) cell line. We divided the groups as follows: negative 
control cells without plasmid transfection, vehicle control cells transfected with the PEGFP-N1 vector, and experimental 
cells transfected with the pEGFP-N1-p53/MAR vector. Cells in each well of the vehicle control and experimental groups 
were transfected with 1.6 μg of plasmid and 3 μL of liposome. The cellular morphology of each group was analysed 
using green fluorescence microscopy at 12, 24, 36 and 48 h. Then, statistical analysis of the apoptosis rates among 
the three groups was performed using SPSS. The ultrastructures of the cells were observed via transmission electron 
microscopy after transfection for 24 h. Morphological analysis showed that the cells of the experimental group were 
shrunken and reduced in size and their intercellular connections had disappeared. Additionally, the apoptosis rate in the 
experimental group was significantly higher than that in the control groups and the cellular microstructure showed that 
heterochromatin and apoptotic bodies were found in the experimental group. In conclusion, compared with the control 
groups, the pEGFP-N1-p53/MAR plasmid can effectively promote Hep3B cell apoptosis in vitro. 
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ABSTRAK
Kanser selalu menimbulkan masalah besar yang mengancam kesihatan manusia. Kebelakangan ini, penggunaan terapi 
gen dalam penyelidikan kanser telah meningkat dengan ketara. Kajian ini bertujuan untuk membina sebuah rekombinan 
vektor ekspresi eukariot bukan virus, jenis liar, pEGFP-N1-p53/MAR dan mengesahkan mekanisme tindakan dalam sel 
kanser secara in vitro. Kajian ini memberikan satu strategi baru untuk terapi gen p53 melalui peraturan matriks pelekatan 
rantau (MAR), berpotensi meletakkan asas yang kukuh untuk penubuhan bioreaktor protein antikanser. Gen p53 diklon 
daripada darah periferi manusia dan gen MAR telah diamplifikasi daripada tisu hati ayam. Vektor ekspresi rekombinan 
eukariot pEGFP-N1-p53/MAR telah dibangunkan menggunakan sistem replikasi sendiri E. coli. LipofectamineTM 2000 telah 
digunakan sebagai ejen transfeksi untuk menghantar plasmid ke dalam titisan sel manusia karsinoma hepar (HEP3B). 
Kami membahagikan kumpulan seperti berikut: Sel kawalan negatif tanpa transfeksi plasmid, sel kawalan penghantaran 
transfeksi dengan vektor PEGFP-N1 dan sel uji kaji transfeksi dengan vektor pEGFP-N1-p53/MAR. Sel dalam telaga 
setiap kawalan sarana dan kumpulan uji kaji telah ditransfeksi dengan 1.6 μg plasmid dan 3 μL liposom. Morfologi sel 
setiap kumpulan dianalisis menggunakan mikroskop hijau pendarfluor pada 12, 24, 36 dan 48 jam. Kemudian, analisis 
statistik pada kadar apoptosis antara ketiga-tiga kumpulan telah dijalankan menggunakan perisian SPSS. Ultrastruktur 
sel telah diperhatikan melalui penghantaran elektron mikroskop selepas transfeksi selama 24 jam. Analisis morfologi 
menunjukkan bahawa sel kumpulan uji kaji telah dikecut dan dikurangkan saiznya serta sambungan intersel telah 
hilang. Di samping itu, kadar apoptosis dalam kumpulan uji kaji adalah jauh lebih tinggi daripada kumpulan kawalan 
dan mikrostruktur sel menunjukkan bahawa jasad heterokromatin dan apoptotik telah ditemui dalam kumpulan uji 
kaji. Kesimpulannya, berbanding dengan kumpulan kawalan, plasmid pEGFP-N1-p53/MAR berkesan menggalakkan 
sel apoptosis Hep3B secara in vitro. 
Kata kunci: Gen p53; matriks pelekatan rantau (MAR); mikrostruktur sel; morfologi sel;  terapi gen; vektor bukan virus
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INTRODUCTION
Gene therapy can be defined as the transfer of foreign 
genetic materials to a patient to prevent, treat, or cure 
a disease (Wang et al. 2015). Recently, there has been a 
significant increase in the development of gene therapies 
for the treatment of cancer, such as the transfer of suicide 
genes and tumour suppressor genes (Seth 2005). The p53 
gene is the tumour suppressor gene most often associated 
with human tumours. More than 50% of cancers are 
associated with deletion and mutation of the p53 gene, 
which has now become one of the most important targets 
for cancer treatment (Buyukpinarbasili et al. 2016). The 
development of both viral and non-viral gene delivery 
methods is necessary to help therapeutic genes enter 
cancer cells. A high transfection efficiency of viral vectors 
has been reported; however, they have the potential to 
be mutagenic or immunogenic, and safety concerns have 
significantly restricted their clinical applications (Choi et 
al. 2012; Hafner et al. 2013; Naim 2013). Although the 
development of non-viral systems has suffered from a 
low gene-transfer efficacy, in some cases, their improved 
safety and specificity, greater flexibility and ease of 
manufacturing have rendered them attractive candidates 
for gene therapy (Xu et al. 2011). Therefore, in this article, 
we aim to construct a non-viral p53 vector with a high 
expression efficiency. 
 Active chromatin anchored to the nuclear matrix 
by a matrix attachment region (MAR) is limited to 
free rotation, which can lead to a torsion effect on the 
chromatin structure domain. This is a characteristic 
of MAR that allows for its random integration on the 
chromosome (Bode et al. 1992). Moreover, the single 
strand of MAR that adheres to the nuclear chromatin wire 
ring on the frame easily forms a superhelix and uncoils. 
As the degree of the superhelix increases, the uncoiling 
becomes less rigid. Meanwhile, these factors favour the 
combination of transcriptional regulatory factors and 
boost gene expression (Bode et al. 1992). MAR plays 
important roles, such as improving the expression level of 
genetically modified genes, eliminating gene expression 
differences in an individual and inhibiting the silence of 
exogenous genes. Transgenic studies have demonstrated 
that high-level tissue-specific expression is observed 
only when the core is present in the context of the MARs 
(Forrester et al. 1994). Overexpression of B cell regulator 
of immunoreactive growth hormone (IgH) transcription 
leads to enhanced DNase I sensitivity of endogenous 
immunoglobulin heavy-chain intronic enhancer matrix 
associating regions (Kaplan et al. 2001).
 Based on the research described, we attempted 
to construct a new non-viral recombinant eukaryotic 
expression vector, pEGFP-N1-p53/MAR, for use in gene 
therapy and to build an anticancer protein bioreactor. 
We aimed to transfect HEP3B cells in vitro to verify the 
activity of the p53 gene in this recombinant vector, as this 
was the first time MAR was studied in the regulation of 
the p53 gene in HEP3B cells. Furthermore, the foreign 
gene was introduced into cells by LipofectamineTM 
2000. Liposomes have many advantages as gene 
delivery vehicles, such as a lack of immunogenicity 
and mutagenicity, the ability to complex with relatively 
large amounts of DNA, reliability in transfecting cells and 
ease of preparation (Wang et al. 2015). Enhanced green 
fluorescence protein was observed by green fluorescence 
microscopy. Subsequently, the selection of different 
groups with the same cell culture period was observed 
by transmission electron microscopy. Therefore, by 
comparing the microcellular morphological changes and 
internal changes in the ultrastructures of different groups 
of cells, we determined the inhibition efficacy of HEP3B 
cell growth after transfection with the recombinant 
expression vector.
MATERIALS AND METHODS
SAMPLE COLLECTION AND TEST ANIMALS
The peripheral blood of early lung cancer patients was 
provided by the Third Affiliated Hospital Affiliated of 
Henan University of Science and Technology. The animal 
experimental design and procedures were approved by the 
Institutional Animal Care and Use Committee of Henan 
University of Science and Technology (Henan, People’s 
Republic of China). The chickens were obtained from the 
genetics and breeding laboratory of the Animal Science and 
Technology College at Henan University of Science and 
Technology. Livers were collected from several healthy 
native Hy-Line Variety Brown hens.
RNA EXTRACTION AND REVERSE TRANSCRIPTION
Total RNA was extracted from the peripheral blood of early 
lung cancer patients using Trizol reagent (Takara, Beijing, 
China). The RNA purity and concentration were determined 
by agarose gel imaging systems. The RNA was then stored 
in liquid nitrogen. cDNA was synthesized by reverse 
transcription using the RT kit (Takara, Beijing, China).
GENOMIC DNA EXTRACTION
Genomic DNA was extracted from fresh chicken livers 
using the animal genome DNA extraction kit (Sangon, 
Shanghai, China). The DNA concentration and purity were 
determined using an agarose gel imaging system. The DNA 
was then stored at -20°C.
PRIMER DESIGN AND SYNTHESIS
The p53 gene primers were designed according to the 
human tumour suppressor gene p53 sequence (NCBI 
GenBank: NW_926584.1) with HindIII and BamHI 
restriction sites (Table 1). Amplification of the p53 gene 
sequence was performed using PCR and the size of the p53 
gene fragment was 1183 bp. MAR primers were designed 
based on the chicken α-globin MAR sequence (NCBI 
GenBank: AF098919.2) with XbaI and NotI restriction 
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sites (Table 1), producing a PCR product that was 1044 bp 
in size. All the primers were designed using Primer 5.0 
and synthesized by Shanghai Sangon Biological CO., Ltd.
PCR AMPLIFICATION AND RECOVERY OF TARGET GENES
The PCR amplification reaction system included 10 μL of 
2×Taq PCR Master Mix, 0.6 μL of forward primer, 0.6 μL 
of reverse primer, 1 μL of template and RNase-Free dH2O 
in a total volume of 25 μL. The cDNA of human peripheral 
blood was used as the template to amplify the p53 gene. 
The MAR gene was amplified using the genomic DNA of the 
chicken liver as a template. Amplification was performed as 
described in Table 2. The conditions consisted of 1 cycle of 
pre-degeneration and final extension, followed by 32 cycles 
of denaturation, annealing and extension. PCR products 
were separated by 0.8% agarose gel electrophoresis, 
purified using a purification kit (Sangon, Shanghai, China) 
and sequenced by Shanghai Sangon Biological CO., Ltd.
CONSTRUCTION OF THE RECOMBINANT VECTOR
The pEGFP-N1 vector and p53 gene sequence were 
double-digested with HindIII and BamHI simultaneously 
and then ligated overnight with T4 DNA ligase at 4°. The 
self-replicating system of Escherichia coli was used to 
construct the pEGFP-N1-p53 vector. Both the pEGFP-
N1-p53 vector and MAR were double-digested with NotI 
and XbaI simultaneously and ligated by the T4 DNA ligase 
to construct the pEGFP-N1-p53/MAR eukaryotic expression 
vector. Then, the recombinant vector PEGFP-N1-p53/MAR 
was transformed into E. coli JM110. Positive clones were 
screened by PCR and identified by sequence analysis. The 
recombinant vector was extracted from a transformant 
using the Mini Plasmid kit (Trans, Beijing, China).
CULTURE AND TRANSFECTION OF HEP3B CELLS
HEP3B cells were obtained from the Institute of Basic 
Medical Science at the Chinese Academy of Medical 
Science. The cell lines were characterized by the provider 
using gene profiling analysis and used fewer than 6 months 
after receipt. HEP3B cells were cultured in Minimum 
Essential Medium (HyClone, USA) supplemented with 10% 
foetal bovine serum(v/v) and 1% penicillin/streptomycin 
(v/v) at 37°C in a humidified atmosphere containing 5% 
CO2. Then, 1×105 cells were plated on 12-well plates. Prior 
to the transfection experiments, the cells were plated at 
80% confluence per well in twelve-well plates. The Hep3b 
cells were transfected with plasmids using LipofectamineTM 
2000 reagent (Invitrogen, Carlsbad, CA, USA) according 
to the manufacturer’s instructions. The cells in each 
well of the vehicle control and experimental group were 
transfected with 1.6 μg of plasmid and 3 μL of liposome. 
Then, the cells were divided into three groups as follows: 
PEGFP-N1-p53/MAR, PEGFP-N1 and the normal group 
without any plasmids, which represent the experimental 
group, the vehicle control group and the negative control 
group, respectively.
DETECTION OF MORPHOLOGICAL CHANGES                                 
IN HEP3B CELLS
Both the PEGFP-N1-p53/MAR and PEGFP-N1 vectors carry 
the GFP gene; thus, the transfection efficiency could be 
evaluated by GFP expression. Green fluorescence indicated 
by expression of the GFP gene was observed every 12 h 
after transfection under a fluorescence microscope (CX41, 
Olympus, Tokyo, Japan) for every group. Simultaneously, 
morphological changes in the cells were observed every 12 
h (12 h, 24 h, 36 h, 48 h) after transfection using an inverted 
microscope (Nikon 2000-U; Japan). After transfection for 
48 h, apoptosis was detected using a TUNEL Kit (Roche, 
USA) and statistical analysis of the apoptosis rates among 
the three groups was performed using SPSS 20.0 software.
TRANSMISSION ELECTRON MICROSCOPY (TEM) ASSAY
The transfected cells were collected at 24 h. The collected 
cells were washed three times in 0.1 M sodium phosphate 
buffer at pH7.4 and fixed in 4% glutaraldehyde for 48 h 
at 4°. The fixed cells were washed three times in 0.1 M 
sodium phosphate buffer for 5 min each and post-fixed in 
1% OsO4 and 0.1 M sodium phosphate buffer for two h 
TABLE 1. Primer sequences for PCR
Primers Size/bp
P53 For: 5’-CGCaagcttATGGAGGAGCCGCAGTC-3’Re: 5’-GCCggatccCAGTCTGAATCAGGCCCT-3’ 1183
MAR For: 5’-TATAgcggccgcCACTGTAGCCCTTA-3’Re: 5’-CTACtctagaGCTGGAAATGGCAAAC-3’ 1044
























at 4°. The samples were dehydrated in a gradient ethanol 
series (30%, 50%, 70%, 90% and 100%) and embedded in 
Epon with different labels. Ultrathin sections were cut at 60 
nm using LKB NOVA and examined under a Tecai G2 Spirit 
transmission electron microscope. The morphological 
characteristics of the transfected cells were compared 
among the three groups.
RESULTS AND DISSCUSSION
SUCCESSFUL CONSTRUCTION OF THE                                   
PEGFP-N1-P53/MAR VECTOR
The human tumour suppressor gene p53 sequence was 
amplified by RT-PCR and a single band was obtained 
by 1% agarose gel electrophoresis (Figure 1(a)). The 
sequencing comparison with known sequences (GenBank: 
NW_926584.1) resulted in 99% homology. Using chicken 
MAR gene primers, the gene fragment of chicken MAR was 
amplified by PCR, and a single band was obtained by 1% 
agarose gel electrophoresis (Figure 1(b)). The BLAST result 
showed 99% homology to the NCBI sequence (GenBank: 
AF098919.2). Subsequently, the purified recombinant 
plasmid DNA pEGFP-N1-p53/MAR was separated by 1% 
agarose gel electrophoresis and detected by UV light. The 
plasmid was identified by enzyme digestion (Figure 1(c)) 
and sequenced with universal primers. The recombinant 
eukaryotic expression vector pEGFP-N1-p53/MAR was 
successfully constructed. The recombinant expression 
vector pEGFP-N1-p53/MAR included the human tumour 
suppressor gene p53 and the chicken MAR gene regulatory 
sequence. In addition, the p53 sequence was inserted 
between HindIII and BamHI and the locus of the MAR 
sequence was inserted between NotI and XbaI (Figure 1(d)). 
 The molecular weight of the protein encoded by 
the p53 gene is approximately 53 KD, which is why it 
is called the p53 protein. It is composed of 393 amino 
acid residues and can be detectable in nearly all somatic 
cells (Soussi et al. 1996, 1990). The principle function 
of p53 protein is to integrate the stress response of cells 
to crisis situations, which relays messages that influence 
the structure and function of DNA stability (Levine et al. 
1997). The biological function of the normal p53 protein 
is two-faced in the lives of healthy cells. It acts on the 
damaged cells in G1 and restores the DNA of damaged cells 
before their duplication and fission. However, when cell 
damage occurs beyond the extent to which the p53 gene 
can repair, this gene induces cell apoptosis (Ljungman 
2000; Soussi 2007). Treatments have investigated p53 
gene therapy in combination with radiotherapy, physical 
therapy, chemotherapy and gene therapy targeting other 
genes (Liu et al. 2010; Mandal et al. 2011; Ndoye et al. 
2004; Xu et al. 2002). 
MACROSCOPIC MORPHOLOGY CHANGES IN HEP3B CELLS
Morphological changes in the transfected HEP3B cells in 
the three groups over time are presented in Figure 2(a). 
(a) Lane M indicates DNA Mark 2000; Lane p53 indicates the p53 gene sequence, (b) Lane M indicates DNA Mark 2000; Lane 
MAR indicates the MAR gene sequence, (c) Lane M indicates DNA Mark 5000; Lane 1 indicates the plasmid DNA pEGFP-N1-p53 
digested with HindIII (only one line: 6900 bp); Lane 2 indicates the plasmid DNA pEGFP-N1-p53/MAR double digested with NotI 
and XbaI (two lines: 5856 bp, 1044 bp); Lane 3 indicates the plasmid DNA pEGFP-N1-p53/MAR digested with HindIII and BamHI 
(two lines: 5717 bp, 1183 bp) and (d) The pattern diagram of the recombinant expression vector pEGFP-N1-p53/MAR
FIGURE 1. Diagram of the recombinant plasmid pEGFP-N1-p53/MAR
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The transfected cells in the negative control group and 
vehicle control group showed normal structural features, 
as indicated by the adherent morphology and integrity of 
the cell junctions (Figure 2(a)-N/P-12～48 h). However, 
as the experiment continued, the morphology of the 
experimental group showed not only cell shrinkage and cell 
size reduction but also the disappearance of intercellular 
connections (Figure 2(a)-E-12～48 h). Many cells died in 
the experimental group at 48 h after transfection (Figure 
2(a)-E-48 h).
 Expression of the GFP protein was observed in both the 
vehicle control and experimental groups of HEP3B cells. 
HEP3B cells in the vehicle control and experimental groups 
showed green fluorescence after transfection (Figure 2(b)-
P/E-24). Cells in the negative control group never showed 
any fluorescence (Figure 2(b)-N-24 h). 
 HEP3B cells are a human hepatoma cell line that 
has a non-functional p53 gene (Cheng et al. 2010). The 
transfection of the recombinant carrier pEGFP-N1-p53/
MAR to HEP3B cells excludes the possibility of the 
HEP3B cells producing the p53 protein. The reporter 
gene EGFP in the pEGFP-N1-p53/MAR carrier can be used 
to detect the transfection efficiency of the foreign gene 
under fluorescence microscopy (Figure 2(b)). After the 
three groups of cells were transfected, the morphology of 
the cells in the negative control and vehicle control groups 
changed minimally over time, and the cells adhered well 
(Figure 2(a)-N/P). By contrast, the experimental group 
was transfected with the recombinant plasmid pEGFP-
N1-p53/MAR, which clearly changed the cell morphology 
(Figure 2(a)-E). After transfection for 12 h, the cells of 
the experimental group began to shrink and an increasing 
number of cells became clearly crinkled and rounded 
from 24 h to 36 h. Morphological studies have shown 
that typical apoptotic cell shrink and their cytoplasm 
condenses (Hacker 2000; Majno & Joris 1995). Large 
amounts of HEP3B cells were apoptotic at 48 h compared 
to that in the control groups when analysing the apoptosis 
rate (Figure 4). The results of this study are consistent 
with research on the wild-type p53 expression product, 
which can inhibit the growth of cancer and induce cell 
apoptosis (Ko & Prives 1996). This study shows that 
the recombinant eukaryotic expression vector pEGFP-
N1-p53/MAR can effectively inhibit the growth of HEP3B 
cells, which could be mediated by the expression of p53 
in cells.
CHANGES IN THE UITRASTRUCTURE OF HEB3P CELLS
As shown in Figure 3, the ultrastructural changes of the three 
groups were analysed at 24 h after transfection, showing 
different features among the groups. Ultrastructural analysis 
of the negative control (Figure 3-A1/A2) and vehicle control 
(Figure 3-B1/B2) groups showed normal rough endoplasmic 
reticulum, mitochondria and nuclear structures. After 
transfection with pEGFP-N1-p53/MAR, however, the cells 
presented severe apoptotic phenomena (Figure 3-C1/C2). 
Rough endoplasmic reticulum dilation and mitochondrial 
swelling appeared in the experimental group. Furthermore, 
heterochromatin and apoptotic bodies appeared and a 
crescent was formed in the nucleus.
 Transmission electron microscopy can observe cell 
structure changes at different stages of apoptosis, which 
is considered to be the classic method of cell apoptosis 
research (Kerr et al. 1972). The ultrastructures of the 
HEP3B cells were observed by transmission electron 
microscopy 24 h after transfection. In the vehicle control 
group, the mitochondria were slightly swelled compared 
with those of the negative control group. This finding 
was due to the slight toxicity of green fluorescent protein 
to HEP3B cells. After observing the nuclear structure, 
(a) Morphological changes in the transfected Hep3b cells among the three groups over time (100×). Arrows point to the part of the cell morphology 
that change over time and (b) Observation of green fluorescence in the Hep3b cells of the three groups at 24 h after transfection under fluorescence 
microscopy at a wavelength of 480 nm (Note: N, negative control group; V, vehicle control group; E, experimental group)
FIGURE 2. Diagram of transfected Hep3B cells in the three groups
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heterochromatin was not found in the two groups (Figure 
3-A2/B2). Cells in the vehicle control had smaller nuclei 
than those in the negative group (Figure 3-A1/B1). This 
result may have been due to the slice angle problem during 
cell sectioning. In addition, the nuclei of the tumour cells 
were irregular and some cells showed multicellular nuclei. 
Therefore, the nuclear structure was smaller and did not 
directly show the difference in the cell structure between 
the two groups. Heterochromatin was found in the cells 
of the experimental group and was concentrated on the 
edge of the nucleus with a typical crescent shape (Figure 
3-C2). Meanwhile, apoptotic bodies were found, the 
mitochondria were swollen and the content of the rough 
endoplasmic reticulum was reduced (Figure 3-C1/C2). The 
ultrastructural morphological characteristics of hepatocyte 
apoptosis include nuclear retraction or fragmentation, cell 
membrane integrity and the formation of apoptotic bodies 
(Saafi et al. 2001). The changes in the ultrastructure of the 
experimental group cells fully demonstrate that transfection 
of the recombinant expression plasmid pEGFP-N1-p53/
MAR can promote the apoptosis of HEP3B cells.
 SPSS (Statistic Package for Social Science) analysis 
of the apoptosis rates among the three groups are shown 
in Figure 4. The apoptosis rate of the experimental group 
was significantly higher than those of the negative control 
group and the positive control group (p<0.05). There was 
no significant difference between the negative and positive 
control groups. All the results of this study have proven 
that in vitro transfection of the pEGFP-N1-p53/MAR vector 
can effectively promote Hep3B cell apoptosis.
CONCLUSION
In this study, we successfully constructed a recombinant 
eukaryotic expression vector with the wild-type p53 gene 
and MAR regulation sequence. This study showed that 
transfection of the pEGFP-N1-p53/MAR vector can inhibit 
the proliferation of HEP3B cells, which can be mediated 
by the expression of p53 in cells. However, future studies 
on the expression of p53 and the role of MAR in conferring 
anticancer properties should be performed, as they will 
provide new research and exploration regarding p53 gene 
therapy. Meanwhile, the successful construction of the 
recombinant eukaryotic expression vector pEGFP-N1-p53/
MAR also lays a foundation for the establishment of an 
anticancer protein bioreactor.
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